Quinoline derivatives for use in the treatment or prevention of viral infection
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 20, 2020
Grant Date -
Feb 1, 2018
app pub date -
Feb 19, 2016
filing date -
Feb 23, 2015
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention relates to a quinoline derivative of formula (I) or anyone of its pharmaceutically acceptable salt, or anyone of its metabolites, for use for treating or preventing a viral infection, in particular a HIV infection or a HIV-related condition in a patient; and then terminating said treatment when: the viral load is low or undetectable; and/or the level of CD4+ cell count is maintained or restored. The present invention further relates to a quinoline derivative of formula (I) as defined in claim 1, or anyone of its pharmaceutically acceptable salts and metabolites, for use for treating or preventing a viral infection, in particular a HIV infection or a HIV-related condition in a patient, for which an ineffectiveness or a decline in a prior anti-retroviral treatment effectiveness has been stated and to a quinoline derivative of formula (I) as defined above, or anyone of its pharmaceutically acceptable salts and metabolites, for use for treating or preventing a viral infection, in particular a HIV infection or a HIV-related condition in a patient, wherein the patient is infected by a drug-resistant viral strain, and more particularly by a drug-resistant HIV strain.
First Claim
Other Claims data not available
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
- 0 Citation Count
- A61K Class
- 0 % this patent is cited more than
- 5 Age
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | Apr 20, 2028 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Apr 20, 2032 |
